87 related articles for article (PubMed ID: 8765669)
21. Anthranilic acid based CCK1 antagonists: the 2-indole moiety may represent a "needle" according to the recent homonymous concept.
Varnavas A; Lassiani L; Valenta V; Berti F; Tontini A; Mennuni L; Makovec F
Eur J Med Chem; 2004 Jan; 39(1):85-97. PubMed ID: 14987837
[TBL] [Abstract][Full Text] [Related]
22. Evidence for a functional role of cholecystokinin receptors in the rat thyroid gland.
Ginda WJ
Folia Histochem Cytobiol; 2001; 39(4):331-4. PubMed ID: 11766768
[TBL] [Abstract][Full Text] [Related]
23. Nonsteroidal progesterone receptor ligands (II); synthesis and SAR of new tetrahydrobenzindolone derivatives.
Kurihara K; Shinei R; Tanabe K; Tabata Y; Kurata Y; Hoshiko S; Okonogi T
Bioorg Med Chem; 2006 Jul; 14(14):4862-78. PubMed ID: 16580209
[TBL] [Abstract][Full Text] [Related]
24. CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level.
Xu XJ; Elfvin A; Hao JX; Fournié-Zaluski MC; Roques BP; Wiesenfeld-Hallin Z
Neuropeptides; 1997 Jun; 31(3):287-91. PubMed ID: 9243527
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of gastric emptying and intestinal transit by amphetamine through a mechanism involving an increased secretion of CCK in male rats.
Doong ML; Lu CC; Kau MM; Tsai SC; Chiao YC; Chen JJ; Yeh JY; Lin H; Huang SW; Chen TS; Chang FY; Wang PS
Br J Pharmacol; 1998 Jul; 124(6):1123-30. PubMed ID: 9720782
[TBL] [Abstract][Full Text] [Related]
26. The neurochemical effects of anxiolytic drugs are dependent on rearing conditions in Fawn-Hooded rats.
Lodge DJ; Lawrence AJ
Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):451-8. PubMed ID: 12691780
[TBL] [Abstract][Full Text] [Related]
27. Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists.
Hughes J; Hunter JC; Woodruff GN
Neuropeptides; 1991 Jul; 19 Suppl():85-9. PubMed ID: 1679213
[No Abstract] [Full Text] [Related]
28. CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins.
Smadja C; Ruiz F; Coric P; Fournié-Zaluski MC; Roques BP; Maldonado R
Psychopharmacology (Berl); 1997 Aug; 132(3):227-36. PubMed ID: 9292622
[TBL] [Abstract][Full Text] [Related]
29. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
Escherich A; Lutz J; Escrieut C; Fourmy D; van Neuren AS; Müller G; Schafferhans A; Klebe G; Moroder L
Biopolymers; 2000-2001; 56(2):55-76. PubMed ID: 11592053
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog.
Fossa AA; DePasquale MJ; Morrone J; Zorn SH; Bryce D; Lowe JA; McLean S
J Pharmacol Exp Ther; 1997 Apr; 281(1):180-7. PubMed ID: 9103496
[TBL] [Abstract][Full Text] [Related]
31. Gastrin receptor antagonist CI-988 inhibits growth of human colon cancer in vivo and in vitro.
Romani R; Howes LG; Morris DL
Aust N Z J Surg; 1996 Apr; 66(4):235-7. PubMed ID: 8611133
[TBL] [Abstract][Full Text] [Related]
32. The effects of central cholecystokinin receptor blockade on hypothalamic-pituitary-adrenal and symptomatic responses to overnight withdrawal from alprazolam.
Abelson JL; Curtis GC; Nesse R; Fantone R; Pyke RE; Bammert-Adams J
Biol Psychiatry; 1995 Jan; 37(1):56-9. PubMed ID: 7893861
[No Abstract] [Full Text] [Related]
33. Pharmacological analysis of CCK(2) receptor ligands using COS-7 and SK-N-MC cells, expressing the human CCK(2) receptor.
Nilsson I; Monstein HJ; Lindström E; Håkanson R; Svensson S
Regul Pept; 2002 Jan; 103(1):29-37. PubMed ID: 11738246
[TBL] [Abstract][Full Text] [Related]
34. Rationally designed "dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988.
Drysdale MJ; Pritchard MC; Horwell DC
J Med Chem; 1992 Jul; 35(14):2573-81. PubMed ID: 1635058
[TBL] [Abstract][Full Text] [Related]
35. Effects of cholecystokinin-B receptor antagonist on dopamine system in tenascin mutant mice.
Fukamauchi F; Wang YJ; Mataga N; Kusakabe M
Neuroreport; 1997 Dec; 8(18):3919-22. PubMed ID: 9462466
[TBL] [Abstract][Full Text] [Related]
36. Use of ex vivo binding to estimate brain penetration and central activity of CCK-B antagonists.
Patel S; Chapman KL; Smith AJ; Heald A; Freedman SB
Ann N Y Acad Sci; 1994 Mar; 713():360-3. PubMed ID: 8185188
[No Abstract] [Full Text] [Related]
37. Synthesis of new 6H-indolo[2,3-b] [1,8]naphthyridines and their specific inhibition of benzodiazepine receptor.
Da Settimo A; Primofiore G; Ferrarini PL; Mori C; Martini C; Pennacchi E; Lucacchini A
Farmaco Sci; 1986 Aug; 41(8):577-85. PubMed ID: 3017748
[TBL] [Abstract][Full Text] [Related]
38. CI-1015. An orally active CCK-B receptor antagonist with an improved pharmacokinetic profile.
Trivedi BK; Hinton JP
Pharm Biotechnol; 1998; 11():481-505. PubMed ID: 9760693
[No Abstract] [Full Text] [Related]
39. A cholecystokinin-B receptor antagonist potentiates GABAergic and glycinergic inhibition in the nucleus of the solitary tract of the rat.
McLean HA; Champagnat J; Denavit-Saubie M
Eur J Neurosci; 1996 Jun; 8(6):1078-84. PubMed ID: 8752577
[TBL] [Abstract][Full Text] [Related]
40. Amide bond replacements incorporated into CCK-B selective "dipeptoids".
Fincham CI; Higginbottom M; Hill DR; Horwell DC; O'Toole JC; Ratcliffe GS; Rees DC; Roberts E
J Med Chem; 1992 Apr; 35(8):1472-84. PubMed ID: 1573640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
